US Patent Issued to Dragonfly Therapeutics on Aug. 5 for "Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen" (Massachusetts Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,377,144, issued on Aug. 5, was assigned to Dragonfly Therapeutics Inc. (Waltham, Mass.).

"Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen" was invented by Jean-Marie Cuillerot (Somerville, Mass.), Mark DeRose (Wilmington, Mass.), Christopher Ryan Morgan (Southborough, Mass.), Michael C. Naill (Stow, Mass.) and Avni Shah (Framingham, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure relates to methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen such as HER2. Provided are uses of the multi-specific bindi...